Charles Schwab’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $85.5M | Buy |
|
|||||
|
2025
Q1 | $108M | Buy |
|
|||||
|
2024
Q4 | $93.6M | Buy |
|
|||||
|
2024
Q3 | $98.5M | Buy |
|
|||||
|
2024
Q2 | $111M | Buy |
|
|||||
|
2024
Q1 | $117M | Sell |
|
|||||
|
2023
Q4 | $133M | Buy |
|
|||||
|
2023
Q3 | $115M | Buy |
|
|||||
|
2023
Q2 | $110M | Buy |
|
|||||
|
2023
Q1 | $122M | Buy |
|
|||||
|
2022
Q4 | $129M | Buy |
|
|||||
|
2022
Q3 | $103M | Buy |
|
|||||
|
2022
Q2 | $99.6M | Buy |
|
|||||
|
2022
Q1 | $87M | Buy |
|
|||||
|
2021
Q4 | $97.3M | Buy |
|
|||||
|
2021
Q3 | $81.3M | Buy |
|
|||||
|
2021
Q2 | $51.4M | Buy |
|
|||||
|
2021
Q1 | $43.9M | Sell |
|
|||||
|
2020
Q4 | $60.9M | Buy |
|
|||||
|
2020
Q3 | $51.9M | Buy |
|
|||||
|
2020
Q2 | $76.8M | Buy |
|
|||||
|
2020
Q1 | $50.4M | Buy |
|
|||||
|
2019
Q4 | $48.7M | Buy |
|
|||||
|
2019
Q3 | $33.1M | Buy |
|
|||||
|
2019
Q2 | $40.1M | Buy |
|
|||||
|
2019
Q1 | $39.6M | Buy |
|
|||||
|
2018
Q4 | $35.7M | Buy |
|
|||||
|
2018
Q3 | $38.4M | Buy |
|
|||||
|
2018
Q2 | $35.4M | Buy |
|
|||||
|
2018
Q1 | $28.8M | Buy |
|
|||||
|
2017
Q4 | $30M | Buy |
|
|||||
|
2017
Q3 | $29.8M | Buy |
|
|||||
|
2017
Q2 | $27.1M | Buy |
|
|||||
|
2017
Q1 | $24.2M | Buy |
|
|||||
|
2016
Q4 | $21.1M | Buy |
|
|||||
|
2016
Q3 | $22.1M | Buy |
|
|||||
|
2016
Q2 | $17.5M | Buy |
|
|||||
|
2016
Q1 | $18M | Buy |
|
|||||
|
2015
Q4 | $21.9M | Buy |
|
|||||
|
2015
Q3 | $20.4M | Sell |
|
|||||
|
2015
Q2 | $41.4M | Buy |
|
|||||
|
2015
Q1 | $35.1M | Buy |
|
|||||
|
2014
Q4 | $21.3M | Buy |
|
|||||
|
2014
Q3 | $15.5M | Buy |
|
|||||
|
2014
Q2 | $12.7M | Buy |
|
|||||
|
2014
Q1 | $13.2M | Buy |
|
|||||
|
2013
Q4 | $12.4M | Buy |
|
|||||
|
2013
Q3 | $11.9M | Buy |
|
|||||
|
2013
Q2 | $8.26M | Buy |
|